Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.44 |
| ▸ | F10 | P00742 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14202644 | 0.86 | MAPT (0.46) | SMN1; SMN2MAPTTDP1NSD2ALDH1A1 | |
| SCHEMBL10778415 | 0.81 | MAPT (0.56) | SMN1; SMN2MAPTTDP1MAPK1NSD2 | |
| SCHEMBL26192060 | 0.81 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTMRGPRX4TDP1MAPK1 | |
| SCHEMBL9339370 | 0.80 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTMRGPRX4TDP1MAPK1 | |
| SCHEMBL8872859 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTTDP1MAPK1NR4A2 | |
| SCHEMBL14202651 | 0.79 | MAPT (0.46) | SMN1; SMN2MAPTTDP1MAPK1NR4A2 | |
| SCHEMBL16666454 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2MAPTMRGPRX4TDP1MAPK1 | |
| SCHEMBL27973888 | 0.79 | NR4A2 (0.74) | MRGPRX4NR4A2MAOBALDH1A1 | |
| SCHEMBL69684 | 0.79 | NSD2 (0.63) | MAPTTDP1MAPK1NSD2ESR1 | |
| SCHEMBL9368330 | 0.78 | MRGPRX4 (0.76) | SMN1; SMN2MRGPRX4NR4A2MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8062768-B2 | Compound comprising phenyl pyridine units | GENERAL ELECTRIC COMPANY (US) | 2011-11-22 | — | — | US | disclosed |
| US-8039125-B2 | Compound comprising phenyl pyridine units | GENERAL ELECTRIC COMPANY (US) | 2011-10-18 | — | — | US | disclosed |
| US-20090289547-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | GENERAL ELECTRIC COMPANY (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090289224-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | GENERAL ELECTRIC COMPANY (US) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090289547-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | C1S, C3AR1, CRY1 | SMN1; SMN2 4382/4885MAPT 3682/4885MRGPRX4 975/4885 |
| US-20090289224-A1 | COMPOUND COMPRISING PHENYL PYRIDINE UNITS | C1S, C3AR1, CRY1 | SMN1; SMN2 4382/4885MAPT 3682/4885MRGPRX4 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.